Perseid Receives Milestone Payment Under CTLA4-Ig Collaboration With Astellas Pharma
Perseid claimed that its CTLA4-Ig product candidates (designated as MAXY-4) are designed for the treatment of a broad array of autoimmune disorders, including rheumatoid arthritis and transplant rejection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.